Regulatory-grade biomedical datasets and drug target lists sold to AI drug discovery labs and biotech companies.
Biomedical Data Marketplaces & Target Discovery
Now is a rare window: OpenAI is paying to create new biology data just as Nature reported a brain microprotein map that could offer Alzheimer’s clues and Wired described nanoparticles that deliver mRNA straight to tumors. That convergence makes curated, legally sourced, regulatory-grade datasets and target lists especially valuable to AI drug-discovery labs and biotech companies.
Projected Score
as a side gig ☆☆☆☆☆ (0/5)
no money or audience ★☆☆☆☆ (1/5)
with both ★★★☆☆ (3/5)
Want this one researched? Commission the full dossier for $15: we research and write it, and you read it first. Then you choose — pay more to keep it exclusive, or do nothing and it goes public on this site. The score above is our forecast for a dossier we haven’t written yet.
The news behind it
- Sep 16, 2026 MIT Technology Review: AI models need more data about biology, and OpenAI is paying to create it
- Sep 16, 2026 Nature: Map of brain ‘microproteins’ could offer new clues to Alzheimer’s disease
- Sep 16, 2026 Wired: ‘Smart’ Nanoparticles Deliver mRNA Directly to Tumors in New Cancer Therapy
